Aggregate surveillance data only. No patient information and no treatment recommendations.

Interpretation boundaries

What the data can and cannot show

Use the map to find public aggregate evidence, then inspect the contributing rows and reports before drawing a conclusion.

Coverage is uneven

Publicly available antibiograms are not a representative sample of hospitals, laboratories, patients, countries, or health systems. A blank area means no matching mapped evidence in the current release, not an absence of resistance.

Reports are heterogeneous

Facilities use different testing methods, breakpoints, suppression rules, isolate-selection rules, specimen groupings, care settings, and reporting periods. Side-by-side values may not be directly comparable.

Counts have different scopes

A printed n may refer to a drug-tested cell, an organism row, a table, or an entire report. NovAMR separates these evidence classes, but source ambiguity can remain.

Years are not synchronized

Latest available per source can combine different source years. It is useful for current coverage, but it is not a synchronized cross-sectional survey.

Geography can be approximate

A source location may represent a facility, laboratory network, referral population, or reporting jurisdiction. Estimated centers and generated nearest-source regions are labeled and should not be interpreted as patient catchments.

Missing metrics remain missing

Resistance is not inferred from susceptibility. A resistance view can therefore contain fewer calculation rows than the same susceptibility query.

Source access can change

Institutions may move, replace, or remove files. NovAMR retains source metadata and links, but cannot guarantee that every external document remains online.

The Explorer is not clinical guidance

Aggregate antibiograms cannot account for an individual patient's infection site, allergies, prior cultures, dosing, local formulary, or current breakpoint guidance.